He will lose that mansion estate if he does not turn things around here. Whatever money he has, it will not last forever if the company goes bankrupt. He has a lot at stake too. Plus, there is a pride element here. He doesn't want to see Amarin fail because it means that he has failed. No one wants that in their professional profile.
You think that Paul Huff and Colin Stewart left because of bad blood? I don't know if that is the case but interesting theory. Paul Huff returned to his previous employer. Perhaps he only signed on with Amarin for an agreed length of time.
Thank you for posting your discussion with Joe Bruno. I am confused though. If they know that FDA went out of bounds with regards to what was expected for the Adcom and are doing everything possible to to challenge the FDA requirement of outcome for Anchor approval, why are they thinking the probability of approval is low? Is there something they are holding back? It seems that the FDA is legally bound to honor the SPA agreement unless they have good reason not to, which they do not.
Just wondered if having to organize a response to Citizen Petition and associated research would cause a delay for PDUFA?
Also, if the high triglycerides do cause internal stress/breakdown after a person has reached 300 level of triglycerides, can a drug like Vascepa help with cellular repair? This would seem to be the anti-inflammatory benefit, would it not?
Wouldn't having Anchor available to those with Triglyceride levels below 300 help to keep it below 300? I wonder if there have been studies about organ stress/systemic damage/breakdown that starts to take place when the triglycerides reach a certain level
see if the dolphins can use their sonar ability to ensure the FDA approves anchor. They are probably more persuasive than the management team at Amarin.
Excellent add! They could add that information anonymously, I would think but I agree that having that specific data from their patients would add a lot of strength to the letter!